TY  - GEN
AU  - Rup,B
AU  - Pallardy,M
AU  - Sikkema,D
AU  - Albert,T
AU  - Allez,M
AU  - Broet,P
AU  - Carini,C
AU  - Creeke,P
AU  - Davidson,J
AU  - De Vries,N
AU  - Finco,D
AU  - Fogdell-Hahn,A
AU  - Havrdova,E
AU  - Hincelin-Mery,A
AU  - C Holland,M
AU  - H Jensen,P E
AU  - Jury,E C
AU  - Kirby,H
AU  - Kramer,D
AU  - Lacroix-Desmazes,S
AU  - Legrand,J
AU  - Maggi,E
AU  - Maillère,B
AU  - Mariette,X
AU  - Mauri,C
AU  - Mikol,V
AU  - Mulleman,D
AU  - Oldenburg,J
AU  - Paintaud,G
AU  - R Pedersen,C
AU  - Ruperto,N
AU  - Seitz,R
AU  - Spindeldreher,S
AU  - Deisenhammer,F
TI  - Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium
SN  - 1365-2249
PY  - 2015///1117
KW  - Allergy and Immunology
KW  - standards
KW  - Drug Hypersensitivity
KW  - immunology
KW  - Drug Industry
KW  - organization & administration
KW  - Drugs, Investigational
KW  - adverse effects
KW  - Guidelines as Topic
KW  - Humans
KW  - Organizational Innovation
KW  - Organizational Policy
KW  - Reference Standards
KW  - Terminology as Topic
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
UR  - https://doi.org/10.1111/cei.12652
ER  -